Drug intelligence / Profile preview

ALVAC-GM-CSF

Development stage: Unknown
Lead developer: Sanofi Pasteur
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intratumoral

Overview

ALVAC-GM-CSF is a recombinant canarypox virus vector engineered to express granulocyte-macrophage colony-stimulating factor (GM-CSF). It is used in immunotherapy to enhance immune responses by activating dendritic cells, macrophages, and granulocytes. This vaccine vector is designed for local gene expression and is safe in mammalian cells due to its abortive infection cycle, which reduces the risk of genomic integration[2][7].

Targets

CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on ALVAC-GM-CSF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALVAC-GM-CSF.

Explore the full profile